|
CA2557801C
(en)
*
|
2004-03-16 |
2013-06-25 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
|
|
TW200635599A
(en)
|
2004-12-16 |
2006-10-16 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
ATE445608T1
(de)
|
2005-02-23 |
2009-10-15 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
|
|
EP1874787B1
(en)
|
2005-04-15 |
2009-12-30 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
|
EP1910390B1
(en)
|
2005-07-27 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
|
DE602006017566D1
(de)
|
2005-08-30 |
2010-11-25 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
|
ES2358051T3
(es)
|
2005-09-08 |
2011-05-05 |
Boehringer Ingelheim International Gmbh |
Formas cristalinas de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno, métodos para su preparación y su uso para preparar medicamentos.
|
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
AU2007216452A1
(en)
|
2006-02-15 |
2007-08-23 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
US7803778B2
(en)
*
|
2006-05-23 |
2010-09-28 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
|
EP2054426A1
(en)
|
2006-08-15 |
2009-05-06 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
|
JP5372759B2
(ja)
*
|
2006-09-21 |
2013-12-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
|
|
TWI499414B
(zh)
*
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
|
|
EP2086991A1
(en)
|
2006-10-27 |
2009-08-12 |
Boehringer Ingelheim International GmbH |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
|
US7879806B2
(en)
*
|
2006-11-06 |
2011-02-01 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
|
|
WO2008075736A1
(ja)
*
|
2006-12-21 |
2008-06-26 |
Astellas Pharma Inc. |
Ｃ－グリコシド誘導体の製造方法及びその合成中間体
|
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
|
JP2010519273A
(ja)
*
|
2007-02-21 |
2010-06-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
|
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
|
US7838499B2
(en)
|
2007-08-23 |
2010-11-23 |
Theracos, Inc. |
Benzylbenzene derivatives and methods of use
|
|
NZ600110A
(en)
*
|
2007-09-10 |
2013-03-28 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt
|
|
EP2217602B1
(en)
*
|
2007-11-30 |
2018-08-29 |
Boehringer Ingelheim International GmbH |
1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
|
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
|
EP2236137B1
(en)
*
|
2008-01-31 |
2015-06-24 |
Astellas Pharma Inc. |
Pharmaceutical composition for treatment of fatty liver diseases
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
JP5820269B2
(ja)
|
2008-05-22 |
2015-11-24 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
|
|
CN102149280B
(zh)
|
2008-07-15 |
2017-05-24 |
泰拉科斯有限公司 |
氘化苄基苯衍生物及其使用方法
|
|
ME02702B
(me)
*
|
2008-08-22 |
2017-10-20 |
Theracos Sub Llc |
Postupci za pripremu inhibitora sgl t2
|
|
AP2728A
(en)
*
|
2008-08-28 |
2013-08-31 |
Pfizer |
Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
|
|
PE20110383A1
(es)
|
2008-09-08 |
2011-07-15 |
Boehringer Ingelheim Int |
Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
HUE050287T2
(hu)
|
2009-02-13 |
2020-11-30 |
Boehringer Ingelheim Int |
SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
EP4684831A3
(en)
*
|
2009-02-13 |
2026-03-11 |
Boehringer Ingelheim International GmbH |
Sglt2 inhibitor for improving glycemic control
|
|
CN102387783A
(zh)
*
|
2009-02-13 |
2012-03-21 |
贝林格尔.英格海姆国际有限公司 |
包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物、其药物剂型、其制备方法及其在患者中改善血糖控制的用途
|
|
CA2757231A1
(en)
*
|
2009-03-31 |
2010-10-07 |
Boehringer Ingelheim International Gmbh |
1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
US8541380B2
(en)
*
|
2009-06-19 |
2013-09-24 |
Green Cross Corporation |
C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
US8772512B2
(en)
|
2009-07-10 |
2014-07-08 |
Janssen Pharmaceutica Nv |
Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
|
|
AR077859A1
(es)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
|
BR112012007085B8
(pt)
|
2009-09-30 |
2021-05-25 |
Boehringer Ingelheim Int |
processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
|
|
NZ598318A
(en)
|
2009-09-30 |
2014-02-28 |
Boehringer Ingelheim Int |
Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
PH12012500698A1
(en)
|
2009-10-14 |
2016-05-27 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
DK2496583T3
(en)
|
2009-11-02 |
2015-02-02 |
Pfizer |
Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
|
|
WO2011070592A2
(en)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
ES2596291T3
(es)
|
2010-05-11 |
2017-01-05 |
Janssen Pharmaceutica, N.V. |
Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
|
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
CA2807687C
(en)
|
2010-08-12 |
2019-01-08 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
WO2012109996A1
(zh)
*
|
2011-02-18 |
2012-08-23 |
上海璎黎科技有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
CN103596944B
(zh)
|
2011-04-13 |
2017-02-22 |
詹森药业有限公司 |
可用作sglt2的抑制剂的化合物的制备方法
|
|
WO2012146075A1
(zh)
*
|
2011-04-25 |
2012-11-01 |
北京普禄德医药科技有限公司 |
一种钠依赖性葡萄糖转运蛋白抑制剂及其制备方法和用途
|
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
US20130137646A1
(en)
|
2011-06-03 |
2013-05-30 |
Boehringer Ingelheim International Gmbh |
Methods of treatment, pharmaceutical compositions and uses thereof
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2013038429A2
(en)
|
2011-09-13 |
2013-03-21 |
Panacea Biotec Ltd. |
Novel sglt inhibitors
|
|
RU2666530C2
(ru)
|
2012-01-12 |
2018-09-11 |
Йейл Юниверсити |
Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
|
PT2981269T
(pt)
|
2013-04-04 |
2023-10-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
|
TR201901110T4
(tr)
|
2013-04-05 |
2019-02-21 |
Boehringer Ingelheim Int |
Empagliflozinin terapötik kullanımları.
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HK1215378A1
(zh)
|
2013-04-18 |
2016-08-26 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP2895490B1
(en)
|
2013-09-27 |
2016-10-19 |
Sunshine Lake Pharma Co., Ltd. |
Glucopyranosyl derivatives and their uses in medicine
|
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
|
CN105828815B
(zh)
*
|
2013-12-17 |
2020-03-27 |
勃林格殷格翰动物保健有限公司 |
猫科动物中代谢紊乱的治疗
|
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
|
PL3485890T3
(pl)
*
|
2014-01-23 |
2023-08-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
|
|
KR102662473B1
(ko)
|
2014-04-01 |
2024-05-03 |
베링거잉겔하임베트메디카게엠베하 |
말과 동물에서 대사 장애의 치료
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
EA201790070A1
(ru)
|
2014-06-24 |
2017-10-31 |
Дзе Юниверсити оф Канзас |
Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
DK3197429T3
(da)
|
2014-09-25 |
2024-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
|
|
MX386778B
(es)
|
2015-03-09 |
2025-03-19 |
Intekrin Therapeutics Inc |
Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
|
|
WO2017032799A1
(en)
|
2015-08-27 |
2017-03-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Liquid pharmaceutical compositions comprising sglt-2 inhibitors
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
RU2018120330A
(ru)
|
2015-11-02 |
2019-12-04 |
Йейл Юниверсити |
Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
|
|
WO2017141202A1
(en)
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
|
AU2017357589B2
(en)
|
2016-11-10 |
2023-05-11 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2018187350A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
EA202092727A1
(ru)
|
2018-05-14 |
2021-04-20 |
Рита Фармасьютикалз, Инк. |
Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
CN113993865B
(zh)
*
|
2019-07-05 |
2023-09-22 |
山东丹红制药有限公司 |
一种SGLTs抑制剂的晶型及其应用
|
|
MY209787A
(en)
*
|
2019-07-26 |
2025-08-04 |
Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd |
Sglts/dpp4 inhibitor and application thereof
|
|
WO2021105152A1
(en)
|
2019-11-28 |
2021-06-03 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
|
BR112022016360A2
(pt)
|
2020-02-17 |
2022-10-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
|
|
US11801234B2
(en)
|
2020-03-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
WO2023006747A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
|
EP4376829A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
|
CA3256728A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING SGLT-2 INHIBITORS
|
|
TW202500160A
(zh)
|
2023-03-06 |
2025-01-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
|
|
TW202508455A
(zh)
|
2023-05-24 |
2025-03-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
|
|
WO2024240632A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|